Company Filing History:
Years Active: 2023
Title: Yejin Hwang: Innovator in Biotherapeutics
Introduction
Yejin Hwang is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of biotherapeutics, particularly in the development of innovative compounds for treating various disorders. With a total of 3 patents to his name, Hwang is recognized for his impactful research and advancements in medical science.
Latest Patents
Hwang's latest patents include groundbreaking work on substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors. This patent provides a compound of Formula (I) or pharmaceutically acceptable salts, along with methods for using the compound to treat disorders associated with HPK1. Another notable patent involves 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds. This invention offers a compound of Formula (I) or pharmaceutically acceptable salts and methods for treating or preventing inflammatory and autoimmune diseases, particularly neuroinflammation diseases.
Career Highlights
Yejin Hwang is currently associated with 1st Biotherapeutics, Inc., where he continues to push the boundaries of biotherapeutic research. His work is characterized by a commitment to developing effective treatments that address critical health issues.
Collaborations
Hwang collaborates with talented individuals in his field, including Jinhwa Lee and Suyeon Jo. These partnerships enhance the innovative potential of his research and contribute to the success of their projects.
Conclusion
Yejin Hwang is a distinguished inventor whose work in biotherapeutics is paving the way for new treatments and therapies. His patents reflect a dedication to improving health outcomes through innovative science.